Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Creon for Glucose Metabolism and Exocrine Function in Chronic Pancreatitis
NCT07314489Phase 1Recruiting
- Sponsor
- Shanghai Changzheng Hospital
- Start
- Apr 2025
- Primary completion
- Dec 2026
- Modality
- Replacement Enzymes
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of pancreatin in chronic pancreatitis (CP) and pancreatic exocrine insufficiency (EPI), sponsored by Shanghai Changzheng Hospital. Primary endpoint: Changes in glucose profile at 3 months. Started Apr 2025; status: recruiting.
02
Drugs
pancreatin
03
Conditions
chronic pancreatitis (CP)pancreatic exocrine insufficiency (EPI)
Beyond the preview
Go deeper on NCT07314489.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07314489.